This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib.
Undifferentiated Pleomorphic Sarcoma
This is a single-arm open-label window of opportunity clinical study assessing the impact of pre-treatment with palbociclib.
Palbociclib and Pembrolizumab in Undifferentiated Pleomorphic Sarcoma (UPS)
-
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States, 52242
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to
ALL
No
John Rieth,
John Rieth, MD, PRINCIPAL_INVESTIGATOR, University of Iowa Hospitals & Clinics
2028-07